Shift of phosphorus from extracellular to intracellular compartments, decreased gastrointestinal absorption, and increased urinary losses, are the primary mechanisms of hypophosphatemia ...

The Business Research Company's X-linked Hypophosphatemia Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034 The Business Research Company's Latest Report Explores ...

Injectafer isn’t likely to cause any long-term side effects. However, some people may experience severe hypophosphatemia. Very rarely, Injectafer may also cause long-lasting skin discoloration ...

Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia ...

Background and Aims Hypophosphatemia is a common yet often overlooked metabolic disturbance in critically ill children, linked to prolonged mechanical ventilation, extubation failure, extended ...

Retifanlimab-dlwr (Zynyz) was granted approval from the FDA for treatment of locally recurrent or metastatic squamous cell ...

The primary outcome measure will be incidence of hypophosphatemia. Secondary outcomes include weight gain, oedema, other electrolyte distortion, length of hospital admission, admission to the ...

Conditions that are often considered metabolic bone disorders include osteoporosis, osteomalacia, rickets, hypophosphatemia, and Paget’s disease. Most commonly, these disorders are caused by ...

WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in US Improves access for patients living with osteoporosis and ...

Recent studies have highlighted the deleterious role of high phosphate intake in hypertension by means of sympathetic overactivation, yet the underlying mechanisms remain unclear. Dietary phosphate ...